Table 2.
Differences by treatment group in mean change in quality of life from ED to follow-up periods
| HRQL measure (time point) | Difference in mean change in HRQL (magnesium – placebo)* | P† |
|---|---|---|
| Child self-report total score | ||
| PedsQL Generic Scales | ||
| ED to predischarge | 1.5 | .94 |
| ED to 1-week follow-up | −2.3 | .36 |
| PedsQL Multidimensional Fatigue Scales | ||
| ED to predischarge | 2.8 | .26 |
| ED to 1-week follow-up | −1.4 | .82 |
| PedsQL Sickle Cell Disease Module | ||
| ED to predischarge | −3.2 | .17 |
| ED to 1-week follow-up | −3.5 | .55 |
| Parent self-report total score | ||
| PedsQL Generic Scales | ||
| ED to predischarge | −5.4 | .12 |
| ED to 1-week follow-up | −2.0 | .42 |
| PedsQL Multidimensional Fatigue Scales | ||
| ED to predischarge | −2.7 | .30 |
| ED to 1-week follow-up | −0.5 | .68 |
| PedsQL Sickle Cell Disease Module | ||
| ED to predischarge | −2.4 | .06 |
| ED to 1-week follow-up | −0.4 | .59 |
Detailed sample size numbers are shown in the supplemental tables. In general, sample sizes for child report were 140 to 153 predischarge and 132 to 139 at 1 week. Parent report sample sizes were 130 to 136 both predischarge and at 1 week. Higher HRQL scores represent increased quality of life.
Mean change from HRQL score in magnesium group minus mean change from HRQL score in placebo group (eg, mean change in total HRQL for the magnesium group was 1.5 points higher between the ED and predischarge, but 2.3 points lower at 1-week follow-up).
Unadjusted P value. Using Holm’s method, a value less than .025 at any time would be considered significant. If significance at that level had been observed at any point, the next-lowest P value would be considered significant if below .05.